Treatment of lung cancer targeting MET alterations

Abstract

Recently, therapeutics focusing on the MET exon 14 skipping mutation and MET amplification have entered the spotlight. Clinical trials of tepotinib (VISION trial) and capmatinib (GEOMETRY mono-1 trial) have demonstrated the efficacy of these agents in patients with advanced non-small-cell lung cancer (NSCLC) harboring a MET exon 14 skipping mutation. We are also developing MET inhibitors, such as savolitinib and crizotinib, and antibody-drug conjugates targeting MET, such as Sym01 and telisotuzumab vedotin. In addition, the mechanism of resistance after MET inhibitor therapy and its overcoming strategies have been investigated. In the present report, we outline the development of therapeutics for lung cancer targeting MET alterations.